Empagliflozin improves symptoms, reduces hospitalization in HF patients: EMPEROR-preserved Trial

Patients were grouped as per their baseline age and the influence of age and Empagliflozin effects on various parameters like CVD or HFH (primary outcome), total HFH, rate of decline in estimated glomerular filtration rate, health-related quality of life with the Kansas City Cardiomyopathy Questionnaire–Clinical Summary Score, and frequency of adverse events were investigated.

Results:

In patients on placebo, the incidence of primary outcomes and CVD increased with age.

Empagliflozin reduced primary outcomes, first HFH, and first and recurrent HFH across all age groups.

The effect was similar at ≥75 years or >80 years.

Empagliflozin improved Kansas City Cardiomyopathy Questionnaire–Clinical Summary Score at week 52 and attenuated the decline of estimated glomerular filtration rate without age interaction.

No clinically relevant differences in adverse events between empagliflozin and placebo across the age groups were observed.

Thus, the researchers concluded that Empagliflozin could successfully reduce the primary outcomes and first and recurrent HFH. They further added that it also improved symptoms across a broad age spectrum and High age was not associated with reduced efficacy or meaningful intolerability. 

To read the full article, click here:

Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction [EMPEROR-Preserved]; NCT0305951)

 https://doi.org/10.1016/j.jacc.2022.04.040